Pay in 4 interest-free payments of $7.11 Learn more
Ships within 48 hours · Estimated delivery Aug 25 - Aug 30
At the same time, favorable pricing structures and strong private insurance coverage are supporting premium drug pricing and higher treatment adoption rates
PMID: 36363994
The stock sold off sharply again in the following weeks on what felt like any marginally negative datapoint, ultimately revisiting the $35 area in March, a level below where Novo traded before injectable Wegovy was even approved for obesity
Whether the same outcome generalizes to compounded or research-peptide retatrutide is an open question
The addition of glucagon receptor agonism to the GLP-1R and GIPR activity seen in Tirzepatide is the critical differentiator in Retatrutides pharmacological profile
US$ 22.41
US$ 21.09
US$ 23.45
US$ 28.10
US$ 24.54
US$ 24.19
US$ 27.95
